Persistence of Helicobacter pylon after duodenal ulcer healing is associated with high rates of ulcer relapse. We compared colloidal bismuth subcitrate alone with CBS combined with one of four antibiotic regimens in the treatment of duodenal ulcers. Endoscopy and antral biopsies were performed before treatment and four weeks afterwards. Biopsy The patients were allocated to one of five treatment groups. All patients received CBS 120 mg four times a day for four weeks (DeNol swallow tablets-Gist Brocades). The five treatment groups were group 1, CBS alone (n=43); group 2, CBS with amoxycillin (500 mg three times a day for the first week) (n= 18); group 3, CBS with metronidazole (200 mg three times a day for the first week) (n= 23); group 4, CBS with metronidazole (400 mg three times a day for the first week) (n=26); and group 5, CBS with adjuvant metronidazole (400 mg three times a day) and amoxycillin (500 mg three times a day) both for the first week (n=31). As this is a combination of two studies the first 87 patients were allocated by sequential numbers to groups (1), (2), and (3). The remaining 64 patients were allocated by sequential numbers to groups (4) and (5). The endoscopist and histopathologist did not know to which treatment groups the patients belonged. The microbiologist was aware of the treatment groups but this was necessary because of the testing for resistance before and after treatment.
Persistence of Helicobacter pylon after duodenal ulcer healing is associated with high rates of ulcer relapse. We compared colloidal bismuth subcitrate alone with CBS combined with one of four antibiotic regimens in the treatment of duodenal ulcers. Endoscopy and antral biopsies were performed before treatment and four weeks afterwards. Biopsy specimens were examined for histological evidence of gastritis and by Gram stain and culture for H pylon infection. Altogether 141 patients were allocated to one of five treatment groups. Giving CBS and metronidazole (400 mg tid for 7 days) with and without amoxycillin (500 mg tid) achieved higher clearance rates ofH pylori than treatment with CBS alone (p<0-01).
These two combinations also achieved higher rates of antral gastritis healing than CBS alone (p<0-01 and p<005 respectively). Susceptibility to metronidazole was tested in 29 isolates before and in seven isolates after treatment with metronidazole by disc diffusion test and minimum inhibitory concentration assay. Twenty seven (93%) of the isolates were sensitive before treatment while six of seven (86%) were resistant afterwards. Four of the six resistant strains had acquired resistance during treatment and one ofthese had acquired metronidazole resistance despite concomitant treatment with amoxycillin, to which it remained sensitive. CBS with adjuvant metronidazole at a dose of 400 The patients were allocated to one of five treatment groups. All patients received CBS 120 mg four times a day for four weeks (DeNol swallow tablets-Gist Brocades). The five treatment groups were group 1, CBS alone (n=43); group 2, CBS with amoxycillin (500 mg three times a day for the first week) (n= 18); group 3, CBS with metronidazole (200 mg three times a day for the first week) (n= 23); group 4, CBS with metronidazole (400 mg three times a day for the first week) (n=26); and group 5, CBS with adjuvant metronidazole (400 mg three times a day) and amoxycillin (500 mg three times a day) both for the first week (n=31). As this is a combination of two studies the first 87 patients were allocated by sequential numbers to groups (1), (2) , and (3). The remaining 64 patients were allocated by sequential numbers to groups (4) and (5) . The endoscopist and histopathologist did not know to which treatment groups the patients belonged. The microbiologist was aware of the treatment groups but this was necessary because of the testing for resistance before and after treatment.
Patients were advised to take CBS half an hour before meals and to take the antibiotics with food. Compliance was monitored using tablet counts. The effectiveness of treatment was assessed by endoscopic healing of duodenal ulcers, healing of histological gastritis, and eradication of H pylori.
Endoscopic examination and antral biopsy from two sites within 2 cm of the pylorus were performed before treatment and four weeks after the completion of treatment.
One ofeach pair of biopsy specimens was fixed in 10% buffered formalin, embedded in paraffin wax, and sectioned. Sections were stained with haematoxylin and eosin and examined for evidence of gastritis. The susceptibility to metronidazole of 29 isolates obtained from the 57 patients in groups 4 and 5 was assessed by disc diffusion technique using 5 [ig discs and by minimum inhibitory concentration (MIC) determination. The MIC was done on brain-heart infusion agar with 10% horse blood using a multipoint inoculator. A faintly turbid suspension of isolates in nutrient broth (approximately 106-107 cfu/ml) was used for inoculation. The plates were read after 48 and 72 hours of incubation at 37°C in an atmosphere of CO2 and humidity. Amoxycillin sensitivity was tested using amoxycillin discs (10 ig) and a zone of inhibition of 5 cm diameter and above was taken as sensitive. In the disc diffusion test for metronidazole a zone size of 2 cm diameter and above was considered sensitive.
The results were analysed by Z test.
Results
The ulcer healing rates with different regimens are shown in Table I . Although ulcer healing was better in groups 4 and 5, there was no statistically significant difference between the five groups. There was no significant correlation between ulcer healing and H pylon eradication. Table II summarises the results of H pylori eradication. Group 4 (metronidazole 400 mg) and group 5 (metronidazole 400 mg and amoxycillin 500 mg) had significantly higher rates of H pylori eradication than group 1 (on CBS alone) (p<0-01). Group 2 (amoxycillin 500 mg) and group 3 (metronidazole 200 mg) had intermediate eradication rates but did not differ significantly from groups 1, 4, and 5.
Healing ofhistological gastritis (Table III) was also significantly better in groups 4 and 5 compared with group 1 (p<0 05, p<0 05, and p<001 respectively).
The results of sensitivity testing of paired isolates before and after treatment with metronidazole are shown in Table IV nidazole (500 mg three times a day), and amoxycillin (500 mg three times a day) and achieved 90% eradication rate four weeks after completion of treatment. Some of the patients were given H2 antagonists with the above regimen. No antibiotic toxicity was reported. Marshall et al' improved the H pyloni eradication rate in duodenal ulcer patients from 27% to 70% by adding tinidazole (500 mg twice a day for 10 days) to an eight week course of CBS (120 mg four times a day). Minor toxic effects were more common in patients treated with tinidazole.
A study by Borody et al'4 (including both duodenal ulcer and non-ulcer dyspeptic patients) used a four week combination of CBS (120 mg four times a day), tetracycline (500 mg four times a day), and metronidazole (200 mg four times a day) for two weeks. Toxic effects seem to have been more common with this regimen than with the other above mentioned regimens. The eradication rate of H pylorn eight weeks after treatment was 94%. A follow up of 21 duodenal ulcer patients who were H pylori negative at the eight week stage showed that only three (14%) had become H pylon' positive and all of these positive patients had an ulcer relapse. Interpretations ofthe findings ofthis study are complicated by the fact that some of the patients received amoxycillin rather than tetracycline.
Antibiotics alone or in combination with H2 antagonists have a poor record in eradicating H pylori gastritis despite impressive in vitro sensitivity.'4I This failure seems to be due to the development of antibiotic resistance during treatment. Bayerdorffer et al found that virtually all strains of H pylori treated with a combination of ofloxacin and bismuth developed resistance to ofloxacin during treatment. 16 Goodwin et al found that patients treated with a combination of cimetidine and tinidazole had very high rates of acquired tinidazole resistance. In contrast the development of tinidazole resistance was almost abolished by concomitant treatment with CBS. 17 In the present study of seven patients with persistent H pylori infection, two were infected with resistant strains and four acquired resistance to metronidazole during treatment. Acquisition ofresistance may be a major factor in determining H pylori eradication and seems to be more common than pretreatment resistance. The addition of CBS to metronidazole did not prevent the development of resistance. We assume, but cannot prove, that the persistence of H pylori in these patients is due to resistance rather than early infection, as this concurs with experience of other studies.4 16 All isolates in our study were sensitive to amoxycillin before treatment. Amoxycillin resistance did not develop in the one strain which was tested after treatment with combined amoxycillin and metronidazole and in which metronidazole resistance had developed. A possible explanation for this occurrence is suggested by Hollingsworth et al, '8 
